Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SYNDAX PHARMACEUTICALS, INC.

(SNDX)
  Report
Real-time Estimate Cboe BZX  -  01:40:41 2023-02-07 pm EST
26.23 USD   -1.13%
01/31Stifel Starts Syndax Pharmaceuticals at Buy With $37 Price Target
MT
01/13Insider Sell: Syndax Pharmaceuticals
MT
01/11Transcript : Syndax Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 10:30 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Syndax Announces Participation at Evercore ISI Annual HealthCONx Conference

11/21/2022 | 07:01am EST

WALTHAM, Mass., Nov. 21, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in a fireside chat at the Evercore ISI Annual HealthCONx Conference on Wednesday, November 30, 2022, at 3:30 p.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib (SNDX-5613), a highly selective inhibitor of the Menin–MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

Cision
View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-evercore-isi-annual-healthconx-conference-301683415.html

SOURCE Syndax Pharmaceuticals, Inc.


ę PRNewswire 2022
All news about SYNDAX PHARMACEUTICALS, INC.
01/31Stifel Starts Syndax Pharmaceuticals at Buy With $37 Price Target
MT
01/13Insider Sell: Syndax Pharmaceuticals
MT
01/11Transcript : Syndax Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan..
CI
01/04Syndax Announces Presentation at 41st Annual J.P. Morgan Healthcare Conference
PR
01/03JPMorgan Starts Syndax Pharmaceuticals at Overweight With $41 Price Target
MT
2022Syndax Pharmaceuticals Closes $172.5 Million Common Share Offering
MT
2022Syndax Pharmaceuticals Inc : Results of Operations and Financial Condition, Regulation FD ..
AQ
2022Syndax Announces Closing of Public Offering of Common Stock and Full Exercise of Underw..
PR
2022Goldman Sachs Adjusts Price Target on Syndax Pharmaceuticals to $39 From $35, Maintains..
MT
2022HC Wainwright Adjusts Syndax Pharmaceuticals' Price Target to $33 From $31, Keeps Buy R..
MT
More news
Analyst Recommendations on SYNDAX PHARMACEUTICALS, INC.
More recommendations